These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [VP 16-213 in the treatment of acute leukemia in childhood].
    Author: Esumi N, Arakawa S, Imashuku S.
    Journal: Gan To Kagaku Ryoho; 1983 Mar; 10(3):848-51. PubMed ID: 6576730.
    Abstract:
    Effectiveness and side effects of VP 16-213, a semi-synthetic podophyllotoxin, on acute leukemia and histiocytic medullary reticulosis in childhood was tested. Four cases of refractory acute lymphocytic leukemia, five of acute non-lymphocytic leukemia-one induction failure and 4 in remission--and a case of histiocytic medullary reticulosis were treated with a combination of VP 16-213 (Days 1-5), cytosine arabinoside (Days 1-5) and adriamycin (Day 6). None of the acute lymphocytic leukemia patients yielded a complete response; however, one of them later attained a partial response with modified intermittent administration of VP 16-213 and cytosine arabinoside. A patient with acute non-lymphocytic leukemia who had failed to attain initial remission, achieved a complete response after the second course of the treatment with increased dosages. In the four acute non-lymphocytic leukemia patients in remission, complete remission was maintained more than 4 a months. A case of histiocytic medullary reticulosis demonstrated partial response. The major toxic effects produced by this regimen were marked pancytopenia and vomiting. VP 16-213 appears to be effective for myelocytic and monocytic malignancies in childhood.
    [Abstract] [Full Text] [Related] [New Search]